AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

TELA · NASDAQ · Medical - Devices

TELA Bio

Reinforced tissue matrices for hernia and soft-tissue reconstruction.

$0.7000

After-hours close+0.01 (+2.09%)

At close$0.6857(+5.49%)

Something off on this page? Send us feedback.

Profile

TELA Bio, Inc.TELAHealth Care

Sells single-use OviTex and OviTex PRS reinforced tissue matrices to hospitals for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery. Revenue relies on the licensed Aroa platform, which is also the exclusive manufacturer and supplier for both core portfolios.

Combines ovine-derived extracellular matrix with embroidered polymer reinforcement in tissue matrices for surgical repair. The OviTex portfolio serves ventral, inguinal, and hiatal hernia repair and abdominal-wall reconstruction; OviTex PRS supports plastic and reconstructive surgery where soft-tissue weakness exists.

Sells mainly single-use implants to hospital accounts through a predominantly direct commercial organization in the United States and Europe, supplemented by distributors in selected European markets.

Relies on Aroa Biosurgery as exclusive contract manufacturer and supplier for both core portfolios. Aroa holds OviTex U.S. clearances, while TELA holds OviTex PRS clearances; that license relationship and ongoing regulatory compliance underpin nearly all product revenue.

Company facts

CEOHeather C. Getz

ListedNov 8, 2019

ExchangeNASDAQ

HeadquartersMalvern, PA

CountryUnited States

Employees218

CIK0001561921

ISINUS8723811084

Key statistics

Market cap$31.3M

EPS (ttm)−$0.7700

P/E (ttm)−0.9091

ROE1,248.1%

P/B−2.53

P/S0.3919

Dividend yield—

Beta0.87vs XLV 0.32

Year to date −39.9% · Average volume (30d) 204.0K

Analysts

Price target, next 12 months$3.00+328.6%Median of 8 analysts · vs the Aug 28 close

ConsensusBuy7 of 8 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.7000

High$20.00+2,757.1%

Median$3.00+328.6%

Low$1.25+78.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Dec 1, 2025	Loop Capital Markets	Target				$3
Dec 1, 2025	Lake Street	Reiterate		Buy	$8	$3
Nov 14, 2025	Piper Sandler	Reiterate		Neutral	$8	$1.25
Mar 21, 2025	Piper Sandler	Downgrade	Overweight	Neutral

Earnings

EPS

Estimate−$0.19

ReportedDue Nov 12, 2026

Revenue

Estimate$20.0M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.17	−$0.20	−15.1%	$20.0M	$19.3M	−3.6%	−15.05%
May 12, 2026Q1 FY26	−$0.14	−$0.21	−50.0%	$18.6M	$19.1M	+2.5%	−5.88%
Mar 25, 2026Q4 FY25	−$0.18	−$0.16	+11.1%	$21.0M	$20.9M	−0.8%	+8.11%
Nov 13, 2025Q3 FY25	−$0.17	−$0.19	−11.8%	$21.0M	$20.7M	−1.7%	−9.97%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$18.5M	$20.2M	$20.7M	$20.9M	$19.1M	$19.3M
Gross profit	$12.5M	$14.1M	$14.0M	$13.8M	$12.5M	$13.9M
Operating income	−$10.5M	−$9.1M	−$7.6M	−$6.6M	−$10.5M	−$9.3M
Net income	−$11.3M	−$9.9M	−$8.6M	−$9.0M	−$12.3M	−$11.3M
Diluted EPS	−$0.25	−$0.22	−$0.19	−$0.17	−$0.21	−$0.20
Gross margin	67.6%	69.8%	67.5%	65.9%	65.7%	72.3%
Operating margin	-56.5%	-45.0%	-36.5%	-31.9%	-55.2%	-48.1%

Fiscal years (4-quarter sums)FY21 $29.5M · FY22 $41.4M · FY23 $58.5M · FY24 $69.3M · FY25 $80.3M

Revenue by geography · Q2 FY26

United States$15.5M · 80%

Non-US$3.8M · 20%

Balance sheet, Jun 30, 2026Cash & short-term investments $30.4M · Total debt $56.6M · Total assets $59.7M · Shareholders' equity −$15.9M

Dividends

No dividends on record.

Ownership

Institutions 60.07%26.88M sharesInsiders 5.06%2.26M sharesOther 34.87%15.60M shares

Shares outstanding 44.74M · Float 32.87M · 73.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Essex Woodlands Management, Inc.	7.71M	17.24%	13F	May 4, 2026
EW Healthcare Partners Fund 2-UGP, LLC	7.71M	17.23%	13D	Jun 9, 2026
Nantahala Capital Management, LLC	5.14M	11.50%	13F	May 15, 2026
Jon M. Plexico	2.83M	11.00%	13G	Oct 29, 2024
Stonepine Capital Management, LLC	2.62M	5.85%	13F	May 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 17, 2026	Heather C. Getz	director, officer: Chief Executive Officer	+12,500	$0.6649
Aug 14, 2026	Heather C. Getz	director, officer: Chief Executive Officer	+15,000	$0.6978
Nov 17, 2025	Ew Healthcare Partners Fund 2, L.P.	10 percent owner, other: See Remarks	+3,604,000	$1.11